These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

405 related articles for article (PubMed ID: 27087170)

  • 1. Longitudinal analysis of antibody profiles against plakins in severe drug eruptions: emphasis on correlation with tissue damage in drug-induced hypersensitivity syndrome and drug reaction with eosinophilia and systemic symptoms.
    Takehara A; Aoyama Y; Kurosawa M; Shirafuji Y; Umemura H; Kamiya K; Ushigome Y; Kano Y; Shiohara T; Iwatsuki K
    Br J Dermatol; 2016 Nov; 175(5):944-952. PubMed ID: 27087170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Short- and long-term outcomes of 34 patients with drug-induced hypersensitivity syndrome in a single institution.
    Ushigome Y; Kano Y; Ishida T; Hirahara K; Shiohara T
    J Am Acad Dermatol; 2013 May; 68(5):721-8. PubMed ID: 23182063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of thymus and activation-regulated chemokine (TARC/CCL17) as a potential marker for early indication of disease and prediction of disease activity in drug-induced hypersensitivity syndrome (DIHS)/drug rash with eosinophilia and systemic symptoms (DRESS).
    Ogawa K; Morito H; Hasegawa A; Daikoku N; Miyagawa F; Okazaki A; Fukumoto T; Kobayashi N; Kasai T; Watanabe H; Sueki H; Iijima M; Tohyama M; Hashimoto K; Asada H
    J Dermatol Sci; 2013 Jan; 69(1):38-43. PubMed ID: 23141052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The dynamics of herpesvirus reactivations during and after severe drug eruptions: their relation to the clinical phenotype and therapeutic outcome.
    Ishida T; Kano Y; Mizukawa Y; Shiohara T
    Allergy; 2014 Jun; 69(6):798-805. PubMed ID: 24749495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stevens-Johnson syndrome and toxic epidermal necrolysis due to anticonvulsants share certain clinical and laboratory features with drug-induced hypersensitivity syndrome, despite differences in cutaneous presentations.
    Teraki Y; Shibuya M; Izaki S
    Clin Exp Dermatol; 2010 Oct; 35(7):723-8. PubMed ID: 19874350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cicatrizing Conjunctivitis in a Patient Diagnosed With Drug Reaction With Eosinophilia and Systemic Symptoms/Drug-Induced Hypersensitivity Syndrome but With Features of Stevens-Johnson Syndrome.
    Bohm KJ; Ciralsky JB; Harp JL; Bajaj S; Sippel KC
    Cornea; 2016 Jun; 35(6):888-91. PubMed ID: 27078005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monocytes are involved in the balance between regulatory T cells and Th17 cells in severe drug eruptions.
    Ushigome Y; Mizukawa Y; Kimishima M; Yamazaki Y; Takahashi R; Kano Y; Shiohara T
    Clin Exp Allergy; 2018 Nov; 48(11):1453-1463. PubMed ID: 30112775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequelae in 145 patients with drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms: survey conducted by the Asian Research Committee on Severe Cutaneous Adverse Reactions (ASCAR).
    Kano Y; Tohyama M; Aihara M; Matsukura S; Watanabe H; Sueki H; Iijima M; Morita E; Niihara H; Asada H; Kabashima K; Azukizawa H; Hashizume H; Nagao K; Takahashi H; Abe R; Sotozono C; Kurosawa M; Aoyama Y; Chu CY; Chung WH; Shiohara T
    J Dermatol; 2015 Mar; 42(3):276-82. PubMed ID: 25623158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current Perspective Regarding the Immunopathogenesis of Drug-Induced Hypersensitivity Syndrome/Drug Reaction with Eosinophilia and Systemic Symptoms (DIHS/DRESS).
    Miyagawa F; Asada H
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33670052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characteristics of liver injury in drug-induced systemic hypersensitivity reactions.
    Lee T; Lee YS; Yoon SY; Kim S; Bae YJ; Kwon HS; Cho YS; Moon HB; Kim TB
    J Am Acad Dermatol; 2013 Sep; 69(3):407-15. PubMed ID: 23632341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum Soluble OX40 as a Diagnostic and Prognostic Biomarker for Drug-Induced Hypersensitivity Syndrome/Drug Reaction with Eosinophilia and Systemic Symptoms.
    Mitsui Y; Shinkuma S; Nakamura-Nishimura Y; Ommori R; Ogawa K; Miyagawa F; Mori Y; Tohyama M; Asada H
    J Allergy Clin Immunol Pract; 2022 Feb; 10(2):558-565.e4. PubMed ID: 34757063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum TARC levels are strongly correlated with blood eosinophil count in patients with drug eruptions.
    Komatsu-Fujii T; Kaneko S; Chinuki Y; Suyama Y; Ohta M; Niihara H; Morita E
    Allergol Int; 2017 Jan; 66(1):116-122. PubMed ID: 27497618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential expression profile of Th1/Th2-associated chemokines characterizes Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) and drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms (DIHS/DRESS) as distinct entities.
    Miyagawa F; Hasegawa A; Imoto K; Ogawa K; Kobayashi N; Ito K; Fujita H; Aihara M; Watanabe H; Sueki H; Tohyama M; Asada H
    Eur J Dermatol; 2015; 25(1):87-9. PubMed ID: 25547780
    [No Abstract]   [Full Text] [Related]  

  • 14. Differences in immunological alterations and underlying viral infections in two well-defined severe drug eruptions.
    Hirahara K; Kano Y; Mitsuyama Y; Takahashi R; Kimishima M; Shiohara T
    Clin Exp Dermatol; 2010 Dec; 35(8):863-8. PubMed ID: 20456395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Utility of the lymphocyte transformation test in the diagnosis of drug sensitivity: dependence on its timing and the type of drug eruption.
    Kano Y; Hirahara K; Mitsuyama Y; Takahashi R; Shiohara T
    Allergy; 2007 Dec; 62(12):1439-44. PubMed ID: 17983378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pustular-type drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms due to carbamazepine with systemic muscle involvement.
    Matsuda H; Saito K; Takayanagi Y; Okazaki T; Kashima K; Ishikawa K; Kai Y; Takeo N; Hatano Y; Okamoto O; Fujiwara S
    J Dermatol; 2013 Feb; 40(2):118-22. PubMed ID: 23216243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevated serum osteopontin levels in patients with severe cutaneous adverse drug reactions.
    Suzuki M; Koshikawa S; Watanabe H; Inomata N; Yamaguchi Y; Aihara M; Sueki H
    J Dermatol; 2023 Apr; 50(4):536-540. PubMed ID: 36540013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemokines in Severe Cutaneous Adverse Reactions (SCARs).
    Miyagawa F; Asada H
    Biomolecules; 2021 Jun; 11(6):. PubMed ID: 34204146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms due to lamotrigine differs from that due to other drugs.
    Tashiro Y; Azukizawa H; Asada H; Niihara H; Morita E; Yamauchi T; Mizukawa Y; Kusakabe Y; Numazawa S; Izumi M; Sueki H; Watanabe H
    J Dermatol; 2019 Mar; 46(3):226-233. PubMed ID: 30663091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased ratio of FoxP3+ regulatory T cells/CD3+ T cells in skin lesions in drug-induced hypersensitivity syndrome/drug rash with eosinophilia and systemic symptoms.
    Morito H; Ogawa K; Fukumoto T; Kobayashi N; Morii T; Kasai T; Nonomura A; Kishimoto T; Asada H
    Clin Exp Dermatol; 2014 Apr; 39(3):284-91. PubMed ID: 24635062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.